BiomX Inc. announced that the Company will present data from Part 1 of its ongoing Phase 1b/2a study evaluating the novel phage product candidate, BX004, for the treatment of chronic Pseudomonas aeruginosa (PsA) pulmonary infections in people with cystic fibrosis (?CF?) at the 37th Annual North American Cystic Fibrosis Conference, which is being held November 2-4, 2023, in Phoenix, Arizona. The abstract was selected for an oral presentation at the conference. The Phase 1b/2a data for BX004 will also be available as an e-poster on the virtual congress platform.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.3425 USD | -2.59% |
|
+0.74% | +22.32% |
May. 21 | Transcript : BiomX Inc., Q1 2024 Earnings Call, May 21, 2024 | |
May. 20 | BiomX Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+22.32% | 23.91M | |
+15.58% | 121B | |
+16.60% | 110B | |
+18.75% | 25.93B | |
-24.33% | 19.27B | |
-19.42% | 16.01B | |
-17.95% | 15.66B | |
-46.81% | 14.89B | |
+58.78% | 14.47B | |
+4.91% | 13.91B |
- Stock Market
- Equities
- PHGE Stock
- News BiomX Inc.
- Biomx to Present Data from Ongoing Phase 1B/2A Study Evaluating Bx004 for the Treatment of Chronic Pseudomonas Aeruginosa Pulmonary Infections in Patients with Cystic Fibrosis